Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy
Open Access
- 1 June 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (16), 2653-2659
- https://doi.org/10.1200/jco.2009.27.3003
Abstract
Purpose There has been growing interest in the potential anticancer activity of statins based on preclinical evidence of their antiproliferative, proapoptotic, and radiosensitizing properties. The primary objective of this study was to determine whether statin use is associated with improved clinical outcomes in patients treated with radiotherapy (RT) for prostate cancer. Patients and Methods In total, 691 men with prostate adenocarcinoma treated with curative-intent RT between 1988 and 2006 were retrospectively analyzed. Of those, 189 patients (27%) were using statins, either during initial consultation or during follow-up. Lipid panels were collected (n = 298) a median of 5 months before RT start. Median follow-up was 50 months after RT. Results Statin use was associated with improved freedom from biochemical failure (FFBF; P < .001), freedom from salvage androgen deprivation therapy (FFADT; P = .0011), and relapse-free survival (RFS; P < .001). Improved FFBF for statin users was seen in low-, intermediate-, and high-risk groups (P = .0401, P = .0331, and P = .0034, respectively). The improvement in FFBF with statin use was independent of ADT use or radiation dose. On multivariable analysis, statin use was associated with improved FFBF (P < .001) along with pretreatment prostate-specific antigen ≤ 8.4 (P < .001), stage less than T2b (P = .0111), and Gleason score < 7 (P = .0098). On univariate analysis, pretreatment total cholesterol < 187 (89% v 80%; P = .0494) and low-density lipoprotein (LDL) < 110 (96% v 85%; P = .0462) were associated with improved 4-year FFBF. Conclusion Statin use was associated with a significant improvement in FFBF, FFADT, and RFS in this cohort of men treated with RT for prostate cancer. The favorable effect of statins may be mediated by direct effect or via the LDL-lowering effect of these medications.Keywords
This publication has 53 references indexed in Scilit:
- Mortality Results from a Randomized Prostate-Cancer Screening TrialNew England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Quality of Life and Satisfaction with Outcome among Prostate-Cancer SurvivorsNew England Journal of Medicine, 2008
- Predictive models and prostate cancerNature Reviews Endocrinology, 2008
- Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and TreatmentJournal of Urology, 2007
- Active Surveillance for Prostate Cancer: For Whom?Journal of Clinical Oncology, 2005
- THE CONTEMPORARY MANAGEMENT OF PROSTATE CANCER IN THE UNITED STATES: LESSONS FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR (CAPSURE), A NATIONAL DISEASE REGISTRYJournal of Urology, 2004
- Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Determinants of Prostate Cancer Specific Survival Following Radiation Therapy During the Prostate Specific Antigen EraJournal of Urology, 2003
- Comparing the Costs of Radiation Therapy and Radical Prostatectomy for the Initial Treatment of Early-Stage Prostate CancerJournal of Clinical Oncology, 2002